RCKT
Earnings in 9 days · May 14, 2026 · Before open
Signal
Mixed11
Price
1
Move+1.40%Positive session
Volume
1
Volume0.3× avgLight volume
Technical
1
RSIRSI 48Momentum negative
PRICE
Prev Close
3.56
Open
3.55
Day Range3.53 – 3.68
3.53
3.68
52W Range2.19 – 7.77
2.19
7.77
25% of range
VOLUME & SIZE
Avg Volume
3.4M
FUNDAMENTALS
P/E Ratio
-1.8x
Not profitable
EPS (TTM)
Div Yield
No dividend
Beta
1.97
High vol
Performance
1D
+1.40%
5D
+6.49%
1M
+4.34%
3M
+8.41%
6M
+9.73%
YTD
+2.85%
1Y
-54.01%
Best: 6M (+9.73%)Worst: 1Y (-54.01%)
Quick Read
TrendInsufficient MA data
Momentum
BEARISH
thin 0% gross margin
Valuation
FAIR
P/E not available
Health
MODERATE
CR 6.4 · FCF negative
Neutral
Key MetricsTTM
Market Cap$393.93M
Revenue TTM$0.00
Net Income TTM-$223.12M
Free Cash Flow-$190.47M
Gross Margin0.0%
Net Margin0.0%
Operating Margin0.0%
Return on Equity-65.8%
Return on Assets-67.5%
Debt / Equity0.09
Current Ratio6.38
EPS TTM$-2.01

Intelligence analysis not yet available for this stock. Full AI-powered analysis may be available on the intelligence page.

Health Radar
3 strong3 concern
46/100
Liquidity
6.38Strong
Leverage
0.09Strong
Coverage
-49.0xConcern
ROE
-65.8%Concern
ROIC
-76.4%Concern
Cash
$78MStrong
ANALYST COVERAGE18 analysts
BUY
+38.5%upside to target
Buy
1372%
Hold
317%
Sell
211%
13 Buy (72%)3 Hold (17%)2 Sell (11%)
Full report →
Stock Health
Composite Score
4 of 5 signals bullish
8/10
Technicals
RSI RangeRSI 48 — Bearish momentum
Volume
Volume FlowAccumulation — institutional buying
Fundamentals
Last EarningsBeat estimates
Analyst ConsensusBuy
LiquidityCurrent Ratio 6.38 — healthy liquidity
Upcoming Events
EEarnings Report · After CloseMay 6, 2026
Tomorrow
DEx-Dividend DateAug 3, 2026
In 90 days
PDividend PaymentAug 20, 2026
In 107 days
Technicals
Technical SetupBULLISH
Technicals →

Trend

PullbackGolden Cross · 50D leads 200D by 16.8%

-10.4% vs SMA 50 · +4.6% vs SMA 200

Momentum

RSI47.5
Neutral territory
MACD+0.12
Above zero — bullish momentum · compressing
Market Position
Price Levels
52W High
$7.77+115.2%
EMA 50
$4.17+15.4%
EMA 200
$3.95+9.4%
Current
$3.61
52W Low
$2.19-39.3%
52-Week RangeMid-range
$2.1925th %ile$7.77
Squeeze SetupVolume-based
Moderate Squeeze Setup

Accumulation pattern present — more buying days than selling over the past 20 sessions. Volume conditions support gradual price improvement.

20-Day Money Flow
Acc days:2
Dist days:1
Edge:+1 acc
Volume Context
Avg Vol (50D)5.5M
Recent Vol (5D)
5.4M-2%

Based on volume distribution analysis. Direct short interest data (short float %, days to cover) is not available in current data sources.

Earnings & Analysts

ANALYST ESTIMATES

Consensus of 9 analysts
Analyst revisions:EPS↓ Revised DownRevenue↓ Revised Down

Analyst consensus estimates · Actuals replace estimates as reported

YearRevenue Est.Rev GthEPS Est.EPS GthRangeAnalysts
FY2025
$454545
$102321$888625
-$2.05
±4%
High9
FY2026(current)
$18.2M
$8.7M$27.6M
+3896.9%-$1.03
±14%
High9
FY2027
$18.5M
$3.0M$34.0M
+1.7%-$1.26
±39%
High9
Range confidence:Tight (high)ModerateWide (low)
Earnings HistoryRCKT
Last 8Q
+4.9%avg beat
Beat 6 of 8 quartersMissed 1 Estimates rising
+4%
Q2'24
Q3'24
+9%
Q4'24
+9%
Q1'25
+5%
Q2'25
-4%
Q3'25
+6%
Q4'25
+10%
Q1'26
Beat
Miss
Estimate
Deeper color = bigger beat/miss
* Negative EPS shown at reduced height
Analyst Activity
All ratings →
No recent activity
Goldman SachsNeutral → Hold
May 28
DOWNGRADE
Goldman SachsNeutral → Sell
May 28
DOWNGRADE
JefferiesBuy → Hold
May 28
DOWNGRADE
NeedhamBuy → Hold
May 27
DOWNGRADE
Insider Activity
SEC Filings →
0 Buys/6 SellsNet Selling
Militello JohnSee Remarks
$4K
Feb 18
SELL
Shah GauravCEO
$20K
Feb 18
SELL
Wilson MartinGeneral Counsel
$5K
Feb 18
SELL
Wilson MartinGeneral Counsel
$41K
Feb 13
SELL
Militello JohnSee Remarks
$12K
Feb 13
SELL
Shah GauravCEO
$41K
Feb 13
SELL
Financials

INSTITUTIONAL OWNERSHIP

1
Nuveen, LLC
3.1M
2
abrdn plc
665K
3
Assenagon Asset Management S.A.
99K
4
WEALTH ENHANCEMENT ADVISORY SERVICES, LLC
81K
5
Concurrent Investment Advisors, LLC
71K
6
PROFUND ADVISORS LLC
63K
7
SANDERS MORRIS HARRIS LLC
28K
8
Merit Financial Group, LLC
22K
News & Activity

RCKT News

20 articles · 4h ago

About

rocket pharmaceuticals, ltd is a biotechnology company focused on seeking cures through molecular and gene therapy. we are developing first-in-class treatments for patients with rare and often devastating orphan diseases using a lentiviral-based gene therapy approach. we have developed rewarding partnerships with a number of leading international research institutions as well as with centers of manufacturing and cell processing expertise, while building an internal team to drive the research, development, clinical and regulatory programs. ultimately we aim to launch and globally commercialize innovative gene therapies in disease areas with high unmet need. for more information, please visit www.rocketpharma.com.

Industry
Research and Development in Biotechnology (except Nanobiotechnology)
CEO
Gaurav Shah
PeersHealth Care(7 companies)
Screen sector →
SymbolPriceDay %Mkt CapP/ERev GrwMarginELO
RCKT
$3.61+1.40%$394M1500
$68.99+0.00%$13.4B1500
$91.17+0.00%$12.0B-4239.0%1500
$518.66+0.96%$11.9B-3008.0%1500
$223.70+8.31%$11.4B+6554.5%-2868.8%1500
$76.39+0.00%$10.7B52.9+2325815.3%-19.7%1500
$182.03+0.00%$10.6B1500
Sector avg+1.53%52.9+1166184.9%-2533.9%1500